Almirall granted exclusive rights to commercialise SIM0278 for all indications outside the Greater China region, (Mainland China, Hong Kong, Macau and Taiwan)
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements.
28.02.2022 - DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with . Seite 1
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous28.02.2022 / 01:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Dis.